Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors
- E. Claire Dees
- , Jeffrey R. Infante
- , Roger B. Cohen
- , Bert H. O’Neil
- , Suzanne F. Jones
- , Margaret von Mehren
- , Hadi Danaee
- , Yih Lee
- , Jeffrey A. Ecsedy
- , Mark Manfredi
- , Katherine Galvin
- , Bradley Stringer
- , Hua Liu
- , Omar Eton
- , Howard Fingert
- , Howard A. Burris
- University of North Carolina at Chapel Hill
- Tennessee Oncology
- Sarah Cannon Research Institute
- University of Pennsylvania
- Fox Chase Cancer Center
- Hospital Clinico Universitario de Valencia
- Departments of Medical Oncology
- University of Texas Health Science Center at San Antonio
- Indiana University-Purdue University Indianapolis
- Takeda Pharmaceutical Company
- Forest Laboratories, Inc
- Boston University
Research output: Contribution to journal › Article › peer-review
72
Scopus
citations